Calox International

What Calox International does

Calox International is a Venezuelan pharmaceutical company founded in 1935, specializing in the manufacture and commercialization of generic pharmaceutical products. It operates two industrial facilities in Venezuela — a corporate/industrial site in Los Ruices (Caracas) and a manufacturing plant in Guarenas, Miranda — producing a portfolio of approximately 100+ products across three lines: Genéricos (73+ generic prescription drugs covering cardiovascular, gastrointestinal, CNS, antibiotics, and other therapeutic categories), OTC (16 over-the-counter products including analgesics, vitamins, and cold remedies), and the McK branded line (22 products including the Vivax sub-brand for hormonal contraceptives). The company also operates a pharmacovigilance service for adverse drug reaction monitoring.

Calox distributes its products across Venezuela through institutional customers, pharmacies and pharmacy chains, hospitals, clinics, regional distributors, and general consumers. Since 1996, it has pursued a regionalization strategy, expanding into Central America and the Caribbean, where it now holds the #1 position in generic pharmaceuticals in Costa Rica and the Dominican Republic and operates in El Salvador, Guatemala, Honduras, Nicaragua, and Belize. The company is recognized as the first generic pharmaceutical laboratory in Venezuela, has 90 years of operational history, and in 2025 received Great Place to Work certification. In 2025, Calox also signed an academic cooperation agreement with Universidad Santa María's School of Pharmacy.

The business model is traditional pharmaceutical B2B distribution: Calox manufactures generic drugs at its own facilities and commercializes them through field sales teams and institutional sales channels serving multiple buyer types. Revenue is generated through one-time product sales to wholesale, institutional, pharmacy, and hospital channels. Pricing is not publicly disclosed. Geographic expansion is planned into the Andean region, targeting Colombia, Ecuador, and Peru as the next phase of growth beyond the current 8-country footprint.

Name

Calox International

Legal name

Calox International

Website

https://calox.com

Company type

Private

Founded year

1935

Operating status

Operating

Headcount range

251–500 employees

Short description

Calox International is a 90-year-old Venezuelan pharmaceutical company that manufactures and distributes generic, OTC, and branded pharmaceutical products to institutional buyers, pharmacies, hospitals, and consumers across Venezuela and seven Central American/Caribbean countries.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA), Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

Keywords

• Generic pharmaceutical manufacturing
• Pharmaceutical product distribution
• Over-the-counter medications
• Prescription generic drugs
• Pharmaceutical commercialization

Headquarters

HQ city

Caracas

HQ country

Venezuela

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: Calox International generates revenue through the manufacture and commercialization of generic pharmaceutical products, including prescription generics, OTC medicines, and specialty products under the McK brand. Products are distributed through institutional, pharmacy, hospital, and distributor channels across Venezuela and Central America/Caribbean markets.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Calox International manufactures and commercializes generic pharmaceutical products, including a portfolio of 73+ generic prescription medications, 22+ branded McK specialty products, and 16+ over-the-counter medicines. The company operates its own industrial manufacturing facilities in Caracas and Guarenas, Venezuela, and distributes through institutional, pharmacy, hospital, and regional distribution channels across Venezuela and 7 Central American/Caribbean countries.

Product overview

Calox International is a pharmaceutical company specializing in the manufacturing and commercialization of generic medications since 1935. The company operates three main product lines: Genéricos (73+ generic prescription products covering cardiovascular, anti-infectives, CNS, gastrointestinal, and other therapeutic areas), OTC (16 over-the-counter products for consumer self-care including analgesics, vitamins, and cold remedies), and McK (22 branded products including the Vivax sub-brand for hormonal contraceptives). The portfolio includes proton pump inhibitors (Pantoprazol, Omeprazol), cardiovascular medications (Valsartan-HCT, Biocor, Antaar), antibiotics, CNS medications (Sertralina, Risperidona, Pregabalina), and supplements (ProKids, Sulbutiamina). The company also provides pharmacovigilance services and distributes throughout Venezuela and Central America.

Differentiator

Problem solved

Functional benefit

Brands

• Calox Genéricos: Generic pharmaceutical products line including medications across various therapeutic categories such as cardiovascular, antibiotics, and gastrointestinal drugs.
• Calox OTC
• McK
• Vivax

Products and services

• Genéricos (Generic Pharmaceuticals) A core product line of 73+ generic prescription pharmaceutical products covering therapeutic categories including cardiovascular, anti-infectives, central nervous system, gastrointestinal, respiratory, dermatology, and vitamins. This is Calox's flagship line and represents its primary business since the company's founding in 1935, targeting institutional buyers, pharmacies, hospitals, and clinics in Venezuela and Central America/Caribbean markets.
• OTC (Over-the-Counter Products) A line of 16 over-the-counter pharmaceutical products including analgesics, pediatric and adult vitamins, cold and flu remedies, motion sickness treatments, and digestive products. These products are sold without prescription for consumer self-care through pharmacies and retail channels.
• McK (Branded Pharmaceutical Line) A branded pharmaceutical product line with 22 products including cardiovascular medications (BIOCOR, ANTAAR), antibiotics, and specialty medications. Distributed through institutional, pharmacy, and hospital channels in Venezuela.
• Vivax A sub-brand under the McK product line specializing in hormonal contraceptives, including products such as Veroniq. Targeted at women's health through prescription pharmacy and institutional channels.
• Viajesán An over-the-counter pharmaceutical product for the prevention and treatment of motion sickness. Sold through pharmacy and retail channels without prescription.
• ProKids A nutritional supplement powder containing 10 vitamins and 5 minerals (fortified with iron) formulated for children 6 months to 5 years old to support brain development, immune system strength, and prevention of physical and cognitive development delays. Sold as an OTC supplement through pharmacy channels.
• Veroniq A combined oral contraceptive containing Drospirenona 3mg and Etinilestradiol 0.003mg (ATC code G03AA12) used for pregnancy prevention and hormone-related indications. Prescription product distributed under the Vivax sub-brand through pharmacy and institutional channels.
• Pantoprazol A generic proton pump inhibitor in 20mg and 40mg enteric-coated tablets (ATC code A02BC02) for the treatment of duodenal ulcers, gastric ulcers, GERD, reflux esophagitis, and Zollinger-Ellison syndrome. Sold as a generic prescription product through pharmacy and institutional channels.
• Omeprazol A generic proton pump inhibitor in 20mg enteric-coated microgranule capsules (ATC code A02BC01) for the treatment of gastric and duodenal ulcers, reflux esophagitis, and NSAID-induced gastroduodenal lesions. Sold as a generic prescription product through pharmacy and institutional channels.
• Pinaverium Bromuro A generic gastrointestinal antispasmodic in 50mg and 100mg coated tablets (ATC code A03AX04) for the treatment of irritable bowel syndrome. Sold as a generic prescription product through pharmacy and institutional channels.
• Valsartan-Hidroclorotiazida A generic combination antihypertensive containing Valsartan 80mg and Hydrochlorothiazide 12.5mg (ATC code C09DA03) for the treatment of hypertension in patients not adequately responding to monotherapy. Sold as a generic prescription product through pharmacy and institutional channels.
• Trimebutina A generic intestinal motility regulator and antispasmodic in 200mg tablets (ATC code A03AA05) for the treatment of irritable bowel syndrome and functional dyspepsia. Sold as a generic prescription product through pharmacy and institutional channels.
• Tiocolchicosido A generic central-acting muscle relaxant in 4mg tablets and 8mg capsules (ATC code M03BX05) for the treatment of painful skeletal muscle contractures. Sold as a generic prescription product through pharmacy and institutional channels.
• Tadalafilo A generic selective PDE5 inhibitor in 5mg and 20mg coated tablets (ATC code G04BE08) for the treatment of erectile dysfunction. Sold as a generic prescription product through pharmacy and institutional channels.
• Sulbutiamina A generic synthetic derivative of Vitamin B1 in 200mg coated tablets (ATC code A11DA02) for the treatment of thiamine deficiency states associated with apathy and reduced activity, and functional asthenia. Sold as a generic prescription product through pharmacy and institutional channels.
• Simvastatina A generic HMG-CoA reductase inhibitor (statin) for the treatment of hyperlipidemia and reduction of cardiovascular risk. Sold as a generic prescription product through pharmacy and institutional channels.
• Sertralina A generic selective serotonin reuptake inhibitor (SSRI) in 50mg coated tablets (ATC code N06AB06) for the treatment of major depressive disorder, OCD, panic disorder, PTSD, premenstrual dysphoric disorder, and social phobia. Sold as a generic prescription product through pharmacy and institutional channels.
• Secnidazol
• Risperidona
• Farmacovigilancia (Pharmacovigilance Service) A pharmacovigilance service for the detection, evaluation, and prevention of adverse drug reactions and other medication-related problems. Includes an online reporting form for adverse event reporting, supporting healthcare professionals and consumers across Calox's product portfolio.

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered core and minor.

• Universidad Santa MaríacoreStrategic or Co-development PartnerCalox International signed a Convenio de Cooperación Académica e Interinstitucional (Academic and Interinstitutional Cooperation Agreement) with the School of Pharmacy of Universidad Santa María. This strategic alliance is driven by the conviction that the future of health and well-being in Venezuela is built from the classroom. The partnership combines the academic rigor of USM with Calox's years of experience and technical excellence to support scientific excellence and higher education in the country. The agreement aims to open new doors for knowledge development, research, and comprehensive training of pharmaceutical professionals.
• Dividendo Voluntario Venezuela (DVC)minorStrategic or Co-development PartnerCalox partnered with Dividendo Voluntario Venezuela (@dvc_ve) and Fundación Desarrollo Sustentable de Venezuela (@fundesus_vzla) for environmental volunteering activities, including a reforestation initiative at Parque Nacional Waraira Repano where 58 Calox volunteers planted 68 new trees. The partnership aims to mitigate climate change and protect ecosystems in Caracas.
• Fundación Desarrollo Sustentable de Venezuela (Fundesus)minorStrategic or Co-development PartnerCalox partnered with Fundación Desarrollo Sustentable de Venezuela (@fundesus_vzla) and Dividendo Voluntario Venezuela for environmental volunteering, including reforestation activities at Parque Nacional Waraira Repano. The partnership focuses on sustainability and environmental protection.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• MK (Medicamentos y Productos Farmacéuticos): MK is a Colombian generic pharmaceutical manufacturer with a wide portfolio of affordable medicines distributed across Latin America. It shares Calox's focus on generic and OTC categories and competes in similar pharmacy and institutional channels.
• Laboratorios La Santé: La Santé is a Colombian generic pharmaceutical manufacturer with a wide portfolio of generic medications distributed across Latin America. It competes with Calox in generic categories and shares a similar model of multi-country distribution via pharmacy and institutional channels.
• Procaps: Procaps is a Colombian pharmaceutical manufacturer with a portfolio spanning generics, OTC, and specialty products distributed across Latin America. Its integrated manufacturing and multi-country distribution approach mirrors Calox's operating model.
• Tecnofarma: Tecnofarma is a Latin American pharmaceutical company offering generic and branded products across multiple therapeutic areas. Its regional distribution model and generic focus make it a direct comparable to Calox across LatAm markets.
• Genfar: Genfar is a Latin American generic pharmaceutical manufacturer with broad presence across the Andean and Central American regions. Like Calox, Genfar focuses on affordable generic medicines for institutional and retail pharmacy channels, making it a directly comparable regional generic player.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is the world's largest generic pharmaceutical manufacturer with broad LatAm operations. It competes head-to-head with Calox in generic categories in Costa Rica, the Dominican Republic, and other markets where Calox operates.
• Sandoz (Novartis): Sandoz is a global leader in generics and biosimilars with growing presence in Latin America. Its scale, broad portfolio, and pricing power represent a structural competitive threat to Calox in regional generic markets.
• Eurofarma: Eurofarma is one of the largest pharmaceutical companies in Latin America, offering generics, branded, and OTC products across the region. While much larger than Calox, it competes in similar therapeutic categories and channels.

Regional players

• Unipharm: Unipharm is a Central American pharmaceutical company distributing generic and OTC products across the region. It overlaps with Calox's footprint in Costa Rica, Guatemala, Honduras, and other Central American markets.
• Asofarma: Asofarma is a Latin American pharmaceutical company with strong presence in Central America and the Andean region. It competes with Calox in the generic and branded pharmaceutical segments in overlapping regional markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/caloxvenezuela
• Facebookfacebook.com/caloxvzla
• LinkedInlinkedin.com/company/calox-venezuela
• Instagraminstagram.com/caloxvenezuela

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Calox International